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THE ROLE OF IGPR-1 IN LEUKEMIA CELLS 
SHAWN WANG 
ABSTRACT 
 Leukemia is one of the most deadly diseases, responsible for the highest number 
of childhood cancer cases.  Immunoglobulin-containing and proline-rich receptor-1 
(IGPR-1) is a newly identified protein found to play an important role in human colon 
cancer and angiogenesis. The overall goal of this project was to assess IGPR-1 expression 
in leukemia cell lines and investigate its possible function in the NF-κB pathway, 
specifically the role of inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) in 
the phosphorylation of IGPR-1. The NF-κB pathway, among others, plays a critical role 
in human-T-cell leukemia virus type 1 (HTLV-1) infected T-cells. Our preliminary 
results indicated that IGPR-1 is expressed in leukemia cell lines at variable levels. Further 
experiments demonstrated that IKKβ is involved in the phosphorylation of IGPR-1 as 
treatment of HEK-293 cells ectopically expressing IGPR-1 with an IKKβ inhibitor 
decreased IGPR-1 phosphorylation at Ser220. Likewise, cells treated with 
lipopolysaccharide (LPS), which is known to activate IKKβ, also stimulated the 
phosphorylation of IGPR-1 at Ser220. However, transfection of IGPR-1/HEK293 cells 
with Tax, an oncogene encoded by HTLV-1, decreased phosphorylation of IGPR-1 at 
Ser220. Taken together, our data indicates that activation of IKKβ in the NF-κB pathway 









READER APPROVAL PAGE………………………………………………………….. iii 
ACKNOWLEDGMENTS .............................................................................................. iv	
ABSTRACT .................................................................................................................... v	
TABLE OF CONTENTS ............................................................................................... vi	
LIST OF TABLES ........................................................................................................vii	
LIST OF FIGURES ..................................................................................................... viii	
LIST OF ABBREVIATIONS ......................................................................................... ix	
INTRODUCTION ........................................................................................................... 1	









LIST OF TABLES 
 
 
Table Title Page 
1 Four Categories of Leukemia 2 
   
   
   
   










Figure Title Page 




3 Schematic	of	the	Canonical	NF-κB	Pathway	 19 
4 IGPR-1 Expression in Leukemia Samples 24 
5 IGPR-1 Expression in Leukemia Cell Lines 25 




LPS Stimulates Phosphorylation of IGPR-1 at Ser220  
IKK Promotes Phosphorylation of IGPR-1 at Ser220 
Tax Promotes the Inhibition of Phosphorylation of IGPR-
















   




LIST OF ABBREVIATIONS 
 
AML ................................................................................. Acute Myelogenous Leukemia 
ALL ................................................................................... Acute Lymphocytic Leukemia 
ATL ...............................................................................................Adult T-cell Leukemia 
BPAG-1 ............................................................................ Bullous Pemphigoid Antigen-1 
BSA ............................................................................................. Bovine Serum Albumin 
CACNB2 ......................................................................................................... Calcium β2 
CAM .................................................................................... Cellular Adhesion Molecules 
CLL................................................................................. Chronic Lymphocytic Leukemia 
CML .............................................................................. Chronic Myelogenous Leukemia 
CRC .......................................................................................... Human Colorectal Cancer 
DAPK1 ....................................................................... Death-Associated Protein Kinase 1 
ECL................................................................................... Enhanced Chemiluminescence 
E/R ............................................................................................................ ETV6/RUNX1 
FBS .................................................................................................... Fetal Bovine Serum 
HCT ........................................................... Human Colorectal Adenocarcinoma Cell Line 
HHLA2 ................................................................................. HERV-HLTR-Associating 2 
HTLV-1 ................................................................Human-T-Cell Leukemia Virus Type 1 
HUVEC....................................................................... Human Umbilical Endothelial Cell 
IGPR-1 ...................................... Immunoglobulin-Containing and Proline-rich Receptor-1 
IgSF .................................................................................... Immunoglobulin Superfamily 
IKK ............................................................... Inhibitor of Nuclear Factor Kappa-B Kinase  
	
	 x 
ITIM .................................................... Immunoreceptor Tyrosine-Based Inhibitory Motif 
LPS .................................................................................................... Lipopolysaccharide 
LUBAC ......................................................... Linear Ubiquitin Chain Assembly Complex 
MIA ................................................................................... Melanoma Inhibitory Activity 
NF-κB .................................................................................................. Nuclear Factor κB 
PAE..........................................................................................Porcine Aortic Endothelial 
PECAM-1 ................................................. Platelet Endothelial Cell Adhesion Molecule-1 
PEI ......................................................................................................... Polyethylenimine 
PI3K ................................................................................... Phosphatidylinositol 3-Kinase 
PIC .......................................................................................... Protease Inhibitor Cocktail 
PNGase ......................................................................................... Peptide: N-glycosidase 
PPM1D ........................................................................................ Protein Phosphatase 1D 
PVDF ........................................................................................Polyvinylidene Difluoride 
RPMI ............................................................................. Roswell Park Memorial Institute 
Ser220 .............................................................................................................. Serine 220 
ShRNA ................................................................................................ Short Hairpin RNA 
siRNA ........................................................................................... Small Interfering RNA 
SH3 ......................................................................................................... Src Homology 3 
TAM .............................................................................. Tumor-Associated Macrophages 





Leukemia is cancer of blood-forming cells that originates in the bone marrow and 
progressively moves into the bloodstream. There are four categories of leukemia 
(Almaiman, 2018).When leukemia affects granulocytes and monocytes, it is classified as 
myelogenous, but when it affects lymphocytes, it is said to be lymphocytic. Further 
classification has distinguished between acute and chronic leukemia, with the former 
affecting immature stem cells and the latter mature cells (Almaiman, 2018). All 
categories of leukemia show common symptoms like anemia, fatigue, and frequent 
infections (Kouhpeikar et al., 2019). Leukemia affects individuals of all ages, but its 
significance lies in that it represents 30% of all childhood cancers (Kouhpeikar et al., 
2019). Current treatment options include bone marrow transplantation, chemotherapy, 
and radiation therapy but these may differ for each different category of leukemia 
(Kouhpeikar et al., 2019).  Although there have been many advances in the treatment of 
leukemia, the side effects of chemotherapy and a high chance of relapse lead to an overall 
high mortality rate (Kouhpeikar et al., 2019). Moreover, despite extensive research, the 
cause of leukemia is not fully understood. Therefore, to combat this disease, it is essential 
to explore the molecular basis of the development of leukemia and possible new 







Cell Type Acute Chronic 








Table 1: Four Categories of Leukemia 
 
HEMATOPOIESIS AND DEVELOPMENT OF LEUKEMIA  
In humans, hematopoiesis forms 1011 blood cells per day (T. Whitehead, C. Metayer, J. 
Wiemels, A. Singer, 2016). Blood cells progress through various stages of differentiation 
dependent on the needs of the body. The pathway in which blood cells develop offers an 
explanation for the likelihood of leukemia developing in childhood or adulthood. In the 
womb and shortly after birth, a newborn baby will begin to form billions of pre-T and 
pre-B cells as part of the adaptive immune system (T. Whitehead, C. Metayer, J. 
Wiemels, A. Singer, 2016). As such, this is why in most cases of childhood leukemia, 
pre-T and pre-B cells are affected at an earlier stage of differentiation. However, during 
adolescence the number of pre-T and pre-B stages decreases. This results in adults 
contracting hematopoietic cancers in post-antigen stimulated T and B-cell forms and the 
predomination of the myeloid lineage (T. Whitehead, C. Metayer, J. Wiemels, A. Singer, 
2016). Each classification of leukemia can be a result of a different genetic aberration. 
The common alterations are ETV6-RUNX1, RUNX1-MTG8, DAPK1, and BCR-ABL 
for ALL, AML, CLL, and CML respectively (Sun, Chang, & Zhu, 2017) (Moore, 
Tahinci, Williams, Lee, & Hiebert, 2007) (Fabbri & Dalla-favera, 2016) (Zhou & Xu, 
2015).   
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 In ALL, the most common chromosomal alteration is t(12;21)(p13;q22), which 
forms the fusion gene ETV6/RUNX1 (E/R) (Sun et al., 2017). E/R plays a role in 
multiple pathways that leads to the proliferation and survival of leukemia cells such as 
the activation of PI3K/AKT/mTOR pathway as well as the suppression of P53 signaling 
(Sun et al., 2017). The main chromosomal translocation in AML is t(8;21) which 
generates the fusion protein RUNX1-MTG8 (Moore et al., 2007). RUNX1-MTG8 
activates gene expression in Wnt signaling, a pathway frequently involved in tumor 
formation. This pathway is critical to embryonic development and stem cell self-renewal 
(Moore et al., 2007). Unlike the other types of leukemia, the majority of CLL occurs 
sporadically. Despite this, a reduction of death-associated protein kinase 1 (DAPK1), a 
gene associated with pro-apoptosis, has been identified (Fabbri & Dalla-favera, 2016). 
CML occurs due to a chromosomal translocation that results from the formation of the 
oncogene Bcr-Abl, a constitutive active kinase. This in turn leads to the continued 
activation of the Akt pathway, which is involved in the regulation of apoptosis (Zhou & 
Xu, 2015). 
Although there are certain chromosomal alterations that more commonly cause 
these types of leukemia, a vast number of mutations may occur such as deletions, single 
nucleotide mutations, or DNA methylation changes (T. Whitehead, C. Metayer, J. 
Wiemels, A. Singer, 2016). This in turn leads to three predominant possibilities: changes 
in transcription factors, tyrosine kinases, and epigenetic modifiers. Conversely, despite 
commonly found mutations, in some cases, such as ALL and AML, these mutations are 
insufficient to cause the disease by themselves, suggesting involvement of other genetic 
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and epigenetic factors (T. Whitehead, C. Metayer, J. Wiemels, A. Singer, 2016). 
Although large efforts are made to identify the causes of this disease, only a small portion 
of leukemia cases may be pinpointed to genetics and emerging evidence has now 
implicated environmental exposures, such as pesticide, benzene, and parental smoking, in 
the development of leukemia (T. Whitehead, C. Metayer, J. Wiemels, A. Singer, 2016).  
There has been a far greater emphasis on treatments for leukemia rather that of etiology 
(T. Whitehead, C. Metayer, J. Wiemels, A. Singer, 2016). Although there has been 
substantial progress in leukemia treatment options, further research regarding the 
development of leukemia may lead to more effective and safer treatments for this deadly 
disease.  
 
CELL ADHESION MOLECULES 
Cell Adhesion Molecules (CAMs) are essential for the interactions between neighboring 
cells or between cells and the extracellular matrix. There are five categories of CAMs, 
which include cadherins, selectins, Ig-superfamily, integrins, and hyaladherins (Feng, 
Chen, & Zhang, 2016). CAMs help regulate a variety of functions such as cellular 
differentiation, proliferation, and migration (Nader Rahimi, 2017). However, when these 
cell-cell interactions are changed, they lead to possible progression, metastasis, and 
relapse in cancer patients (Cristina et al., 2018). Some adhesive interactions may also 
allow for cancer cells to prevent apoptosis and destroy the immune system leading to 
tumor progression (Kupsa, Horacek, & Jebavy, 2015). Several CAMs play an important 
	
5 




Many types of CAMs have been well documented for their role in metastasis. Cadherins 
are a cell surface glycoprotein responsible for cell-cell adhesion, most importantly at 
adherens junctions. These transmembrane proteins are characterized by an extracellular 
cadherin domain whose function is Ca2+-dependent (Vestweber, 2008). Vascular 
endothelial (VE)-cadherin is a subtype expressed specifically in the endothelium 
responsible for endothelial cell junctions. Like most CAMs, it provides adhesive 
functions through homotypic binding with neighboring endothelial cells (Akers et al., 
2010). This helps maintain the endothelial barrier and prevent the entry of leukocytes 
(Kupsa et al., 2015).  Furthermore, it is involved in other cellular function such as cell 
proliferation and apoptosis (Vestweber, 2008).  
VE-cadherin has been found to be an important regulator of leukemia cells in both 
acute myelogenous leukemia (AML) and Philadelphia chromosome positive (Ph+) acute 
leukemia. AML cells secrete a signal protein, Vascular Endothelial Growth Factor 
(VEGF) (Kupsa et al., 2015). The binding of VEGF to its receptor causes the 
phosphorylation of the intracellular domain of VE-cadherin. This leads to the activation 
of a downstream kinase pathway involving p38 and ERK1/2 activation resulting in an 
increase in endothelial permeability. Data has shown that by using a monoclonal antibody 
with affinity to VEGFR-2, there was an inhibition of leukemic cell survival, proliferation, 
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and migration (Kupsa et al., 2015). The importance of VE-cadherin is also shown in Ph+ 
acute leukemia, which include CML and Ph+ acute lymphoblastic leukemia (Chen et al., 
2014). Ph+ leukemia occurs due to a translocation of the ABL sequence on chromosome 
9 to chromosome 22 which results in a constitutively active ABL protein tyrosine kinase 
(Chen et al., 2014). Imatinib, a current treatment for Ph+ acute leukemia, acts as a 
protein-tyrosine kinase inhibitor. However, in vivo, mechanisms of resistance have been 
displayed resulting in a lower response and a higher rate of relapse. VE-cadherin has 
been shown to be a possible modulator of drug resistance as increased VE-cadherin 
expression results in a lower sensitivity of leukemia cells to imantanib (Chen et al., 
2014). Additional studies report a reduction of chemotherapy-induced leukemia cell 
death in response to overexpression of VE-cadherin (Chen et al., 2014). Therefore, this 
suggests that VE-cadherin acts as a pro-survival modulator for leukemia cells. The 
mechanism by how it does so is not yet fully understood, so additional research is 
required to elucidate how exactly VE-cadherin can be targeted in leukemia treatment 
(Chen et al., 2014).   
 
IMMUNOGLOBULIN SUPERFAMILY 
Unlike cadherins which have been highly researched in their role in cancer metastasis, the 
immunoglobulin superfamily (IgSF) has been studied less despite also being a major 
factor. IgSFs include hundreds of proteins with diverse functions that involve adhesion or 
cell surface binding. Proteins in the IgSF family include virus receptors, major 
histocompatibility complex class I and II molecules, cell surface glycoproteins, and 
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proteins of the T cell receptor complex (Wai Wong, Dye, & Coombe, 2012). IgSF 
members contain one or more immunoglobulin- (Ig-) like domains, which contain 70-110 
amino acids (Wai Wong et al., 2012). These protein domains typically display a sandwich 
structure made up of two opposing antiparallel β-pleated sheets linked by a disulfide 
bond (Wai Wong et al., 2012). IgSF molecules are mainly membrane surface proteins 
made up of an extracellular region, a transmembrane region, and a cytoplasmic region. 
The extracellular Ig domain is where interactions with other molecules occur followed by 
signal transduction within the cytoplasmic region (Yoshihara, Oka, Ikeda, & Mori, 1991). 
There are various functions of IgSF molecules but they all involve cell adhesion or a 
form of binding which causes specific events to occur at the cell surface (Williams & 
Barclay, 1988). Proteins of this family typically play a role on the cell surface either 
through binding to integrins and carbohydrates (heterophilic adhesion) or other Ig-like 
domains on other cell surfaces (homophilic adhesion). (Huang, Li, & Korngold, 1997) 
(Wai Wong et al., 2012). In addition, IgSF molecules have been documented to play a 
larger role in metastasis (Wai Wong et al., 2012). Metastasis is the spread of tumor cells 
to different parts of the body distant to the location of the primary tumor (Wai Wong et 
al., 2012). The five stages of metastasis include (1) proliferation of tumor cells and 
angiogenesis, (2) invasion of local cells, (3) intravasation, (4) extravasation, and (5) 
metastasis (Wai Wong et al., 2012). IgSF proteins have been discovered to be involved in 




PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1 (PECAM-1) 
PECAM-1 is a glycoprotein of the Ig-superfamily of type I transmembrane CAMs found 
on endothelial cells, circulatory platelets, and neutrophilic granulocytes (Wu, Kurosu, 
Oshikawa, Nagao, & Miura, 2013) (Feng et al., 2016). PECAM-1 mediates the regulation 
of cell adhesion, leukocyte extravasation, and prevention of cell apoptosis. Its physical 
structure is composed of an extracellular domain with 6 homologous regions each 
comprising of 6 subunits of immunoglobulins and an intracellular region, which contain 
two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (Feng et al., 2016). ITIM 
binds to SHP-2, a tyrosine phosphatase, which leads to the phosphorylation of specific 
residues such as Tyr663 and Tyr686 and this results in various cellular functions. 
PECAM-1 inhibits cell apoptosis through modulating proteins in signaling pathways such 
as Akt, Bcl-2, Bcl-x, p38/JNK, caspase, and MAPK (Feng et al., 2016). For example, the 
binding of PECAM-1 to phosphatidylinositide-3 kinase causes the phosphorylation of 
Akt, which increases transcription of anti-apoptotic proteins like Bcl-2 (Feng et al., 
2016). In chronic B lymphocytic leukemia, patients with PECAM-1 expression were 
shown to have a decreased rate of survival (Wu et al., 2013). Similarly to VE-cadherin, 
overexpression of PECAM-1 downregulates apoptosis in response to imantinib in Ph+ 
leukemic cells (Wu et al., 2013). As such, PECAM-1 represents a possible treatment 
option for leukemia, but further investigation on the mechanism of phosphorylation and 




IMMUNOGLOBULIN -CONTAINING AND PROLINE-RICH RECEPTOR-1 
(IGPR-1) 
IGPR-1 is a newly discovered protein within IgSF that is highly expressed in endothelial 
cells. The molecular weight of IGPR-1 was found to be ~55 kDa through Western blot 
analysis (N. Rahimi, Rezazadeh, Mahoney, Hartsough, & Meyer, 2012). However, once 
treated with Peptide: N-glycosidase F (PNGase), an enzyme that hydrolyzes N-glycan 
chains, the molecular weight was found to be 31 kD, suggesting that this molecule is 
highly glycosylated (N. Rahimi et al., 2012). IGPR-1 acts primarily at endothelial 
adherens junctions. Adherens junctions are cell-cell junctions that have major functions 
in transcriptional regulation, cell adhesion, intracellular signaling, and actin cytoskeleton 
fibril formation. Therefore this suggests that IGPR-1 may also function as a regulatory 
role in these events (Wang et al., 2016). Another role of IGPR-1 includes activating and 
downregulating T lymphocytes through its binding with HHLA2 (Wang et al., 2016). 
IGPR-1 consists of a single extracellular Ig domain, a transmembrane domain, 
and an intracellular proline-rich region (N. Rahimi et al., 2012). IGPR-1 presents on the 
surface of endothelial cells as covalently linked cis-dimers and oligomers (Wang et al., 
2016). Through a trans-homophilic dimerization of IGPR-1, this molecule is able to 
regulate phosphorylation at serine 220 (Ser220) (Wang et al., 2016). This 
phosphorylation is needed for IGPR-1 to carry out its primary role in endothelial barrier 
function and angiogenesis. There exists 16 serine/threonine residues within the 
intracellular domain, seven of which have been identified through MS analysis as 
possible phosphorylation sites (Wang et al., 2016). In turn, the intracellular proline rich 
	
10 
domains recognize and interact with Src homology 3 (SH3) containing signaling proteins 
such as bullous pemphigoid antigen-1 (BPAG1), Nck (SPIN90/WISH), calcium β2 
(CACNB2), and melanoma inhibitory activity (MIA) each with different biological 
functions. SPIN90 mediates cell adhesion and actin cytoskeleton reorganization. BPAG 
affects the anchoring of keratin intermediate filaments to hemidesmosomes. CACNB2 
plays a role in regulating calcium entry into cells. MIA is a small protein that interacts 
with proteins at the extracellular matrix (N. Rahimi et al., 2012). IGPR-1 may also play a 
role in actin polymerization through Arp2/3 complex and N-WASP (Woolf et al., 2017).  
The gene sequence of this IGPR-1 exists only in eukaryotes such as primates, the 
horses, guinea pig, bovines, the common shrew, felines, bats, dolphins, canines, and the 
llama, but surprisingly is absent in mice and rats (N. Rahimi et al., 2012). In humans, the 
IGPR-1 gene transcript was found highest in the arteries, veins, and the brain. 
Furthermore, IGPR-1 protein was found in other human organs such as the thymus, small 
intestine, heart, placenta, skin, and kidney (N. Rahimi et al., 2012). However, overall 
IGPR-1 expression can be seen predominantly in epithelial and endothelial cell types.  
 
IGPR-1 REGULATES ANGIOGENESIS 
IGPR-1 serves a critical role in angiogenesis and endothelial cell barrier functions (N. 
Rahimi et al., 2012). Angiogenesis is the process in which new blood vessels are created 
from pre-existing blood vessels. This is especially important in cancer metastasis as 
cancer cells require excess nutrients for growth. Furthermore, angiogenesis is needed for 
tumors to grow larger than 2mm in diameter (N. Rahimi et al., 2012). The discovery that 
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SPIN90 interacts with IGPR-1 helped establish the role that it plays in angiogenesis. In 
porcine aortic endothelial (PAE) cells overexpressing SPIN90, analysis found an increase 
in the formation of capillary tubes (N. Rahimi et al., 2012). Likewise, silencing the 
expression of SPIN90 using small interfering RNA (siRNA) on human umbilical 
endothelial cells (HUVECs) lead to a reduction in capillary tube formation (N. Rahimi et 
al., 2012).  This data provides evidence for the regulation of angiogenesis by IGPR-1. 
 
Figure 1: Schematic of IGPR-1 
(A) IGPR-1 gets phosphorylated at one of the multiple serine phosphorylation sites. The 
proline-rich motifs on IGPR-1 recruits SH3 containing proteins such as BPAG1 and 
Nck90 resulting in downstream biological effects such as intermediate filament 
formation, actin polymerization, vimentin filament assembly, and microtubule 
cytoskeleton network assembly. (B) Known proline rich motifs are shown and compared 




IGPR-1 REGULATES CELL ADHESION  
Expression of IGPR-1 has been shown to regulate cell adhesion and morphology (N. 
Rahimi et al., 2012). PAE cells expressing IGPR-1 tend to have a rectangular shape in 
tight contact with each other as opposed to a more elongated shape in cells not expressing 
IGPR-1 (N. Rahimi et al., 2012). In cell culture, trypsinization is a commonly used 
technique that uses trypsin to break down certain proteins to separate adherent cells from 
the cell culture plate. Experiments have shown that IGPR-1 expressing PAE cells were 
more resistant to trypsinization than PAE cells expressing an empty vector (N. Rahimi et 
al., 2012). This suggests that IGPR-1 not only affects the morphology of these cells, but 
also is involved in cell adherence. Further experiments have also shown the effect of 
IGPR-1 on actin stress fibers (N. Rahimi et al., 2012). In PAE cells expressing IGPR-1, 
actin stress fibers were localized to cell-cell junctions. However, in PAE cells with an 
empty vector, these fibers were more randomly spread and less localized to only cell 
junctions. Therefore, it can be seen that IGPR-1 is crucial in impacting the strength at 
cell-cell junctions. In respect to the localization of actin filaments, it could be seen that 
IGPR-1 also led to an increase in size and number of focal adhesions in PAE cells (N. 
Rahimi et al., 2012). Focal adhesion is important to the regulation of cell migration. Data 
shows that IGPR-1 expressing cells reduce the phosphorylation of paxillin, a protein 
localized to focal adhesion (N. Rahimi et al., 2012). This reduction was shown to inhibit 




ROLE OF IGPR-1 IN COLORECTAL CANCER CELLS 
IGPR-1 has been shown to promote multicellular aggregation in human colorectal cancer 
(CRC) (Woolf et al., 2017). Primary studies showed an increase in IGPR-1 expression in 
CRC biopsies of patients suggesting a possible role of IGPR-1 in tumor development 
(Woolf et al., 2017). To further investigate these effects, IGPR-1 was endogenously 
expressed in human colorectal carcinoma cell line, HCT116, and human colorectal 
adenocarcinoma cell line, HT29 (Woolf et al., 2017). Using a MTT assay, which 
measures cell metabolic activity, IGPR-1 was shown to increase the survival of both 
HCT116 and HT29 compared to a control group (Woolf et al., 2017). In addition, this 
prosurvival effect could also be seen in mice models with the same cell lines. IGPR-1 
expressing tumors grew larger and faster after 3 weeks with respect to a control (Woolf et 
al., 2017). Endogenous IGPR-1 expression was also tested using short hairpin RNA 
(ShRNA) to knockdown the gene expression of IGPR-1 through RNA interference. 
Knockdown of IGPR-1 led to both a decreased survival of HCT116 cells in suspension as 
well as decreased size of the tumor in mice (Woolf et al., 2017). A monoclonal blocking 
antibody (1A12) was created that attempted to target the extracellular domain of IGPR-1 
and prevent its phosphorylation at Ser220. In doing so, the hope was to possibly find a 
therapeutic target for IGPR-1. It was shown that 1A12 antibody decreased overall 
HCT116 cell survival and inhibited tumor volume growth (Woolf et al., 2017). These 





EFFECT OF IGPR-1 ON DOXORUBICIN 
Doxorubicin is a common chemotherapy treatment for a variety of cancers. Multicellular 
aggregation commonly occurs among cancer cells as they function together to lessen the 
effect of chemotherapeutics (Woolf et al., 2017). Expression of IGPR-1 was found to 
increase this resistance in both HT29 and HCT116 cells (Woolf et al., 2017). When 
treated with doxorubicin, this resulted in phosphorylation at Ser220 in a dose-dependent 
manner (Woolf et al., 2017). In vitro studies have shown that that the phosphorylation at 
Ser220 occurs through Akt, a serine/threonine kinase (Woolf et al., 2017). Treatment of 
Ser220 mutant IGPR-1 (A220) in these cells did not lead to an increase in resistance 
displaying the importance of this site. Akt levels were also observed to increase in 
response to doxorubicin. Therefore, it is hypothesized that in response to doxorubicin, the 
tumor cells phosphorylate IGPR-1 at Ser220 through an Akt dependent pathway, which 
in turn leads to drug resistance (Woolf et al., 2017).  
 
HHLA2 
HERV-HLTR-associating 2 (HHLA2) is a newly discovered member of the B7 family 
that helps regulate T-cell function. The structure of HHLA2 is predicted to be composed 
of a type I transmembrane molecule and three extracellular Ig domains (Janakiram, 
Chinai, Zhao, Sparano, & Zang, 2015). HHLA2 binds to receptors located on T cells and 
other immune cells and suppresses proliferation of both human CD4+ and CD8+ T cells 
(Janakiram et al., 2017). Thus, HHLA2 may protect tumor cells from the immune system 
through interaction with these receptors. T cells incubated with HHLA2-Ig were found to 
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decrease the production of many cytokines such as TNF-α, IL-5, IL-10, IL-13, IL-17A, 
IL-22, and IFN-γ (Janakiram et al., 2017). This protein is limited to the trophoblastic cells 
of the placenta, gut, kidney, gallbladder, and breast epithelium (Janakiram et al., 2017). 
However, it is highly expressed in human cancers including breast, lung, prostate, colon, 
thyroid, melanoma, bladder, ovary, pancreas, kidney, liver, and esophagus (Janakiram et 
al., 2015). 
IGPR-1 has been identified as a receptor for HHLA2. This suggests that HHLA2 
may serve a function to also promote angiogenesis through its interaction with IGPR-1. 












Figure 2: Schematic of the interaction between HHLA2 and IGPR-1 
HHLA2 on tumor cells interact with an unidentified receptor resulting in T-cell 
coinhibition and IGPR-1 on endothelial cells causing tumor angiogenesis. HHLA2 is also 
known to bind to immune cells with resulting in an unknown function. HHLA2 
expression on tumor-associated macrophages (TAM) also interacts with IGPR-1 on the 
endothelium. (Adapted from Janakiram et al., 2015) 
 
HUMAN T-CELL LEUKEMIA VIRUS TYPE I ACTIVATION OF NF-κB 
PATHWAY 
 
Human-T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that affects CD4+ T 
lymphocytes resulting in the possible development of adult T-cell leukemia (ATL) in 3%-
5% of infected cases (Lavorgna & Harhaj, 2014). HTLV-1 encodes for the oncoprotein 
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Tax, which regulates gene expression essential to leukemogenesis. Tax effects the 
transcriptional network in these cells through constitutive activation of many 
transcription factors, for example, nuclear factor κB (NF-κB) in the cytoplasm and the 
cis-Golgi (Lavorgna & Harhaj, 2014). This leads to downstream signaling pathways that 
regulate gene expression in the nucleus, crucial for HTLV-1 infected T-cell proliferation 
and survival (Pujari, Hunte, Thomas, & Weyden, 2015). NF-κB activation is dependent 
on inhibitor of κB kinase (IKK) complex activation by Tax. Tax also further accentuates 
NF-κB activation by inactivating A20 and cyclindromatosis, two negative regulators of 
NF-κB (Pujari et al., 2015). The IKK complex is made up of the catalytic kinase subunits, 
IKKα and IKKβ, and the regulatory unit, IKKγ (also known as NEMO). There are two 
different NF-κB pathways, canonical (classical) and noncanonical (alternative), based on 
extracellular stimuli and the specific receptors activated (Pujari et al., 2015). In the 
classical pathway, emerging studies have shown that Tax causes the movement of linear 
ubiquitin chain assembly complex (LUBAC) to IKK and this forms the IKK complex-
associated Lys63/Met1-linked hybrid polyubiquitin chains (Shibata et al., 2017). This 
leads to trans-autophosphorylation of critical serine residues and IKK activation (Hinz & 
Scheidereit, 2014). Upon phosphorylation, the two kinase subunits of IKK dimerize and 
phosphorylates IκB on two serine residues through an interaction with IKKγ (Hinz & 
Scheidereit, 2014). As a result, IκB ubiquitination occurs and subsequent breakdown by a 
proteasome results in the nuclear translocation of NF-κB heterodimers. Data has shown 
that for NF-κB activation to occur in this pathway, both phosphorylation and degradation 
of IκB and phosphorylation of the p65 subunit of NF-κB at Ser534 need to occur (Bai, 
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Ueno, & Vogt, 2010). Akt, a key enzyme activated by phosphatidylinositol 3-kinase 
(PI3K), phosphorylates IKKα and this leads to the phosphorylation at Ser534 by IKKα 
and IKKβ. These events together constitutively activate NF-κB resulting in chronic 







Cell surface receptor activation results in the recruitment of adapter proteins and E3 
ligases, such as LUBAC, which form non-degradative Ub chains (K11, K63, and M1). 
IKK complex is recruited to upstream ubiquitin polymers. The phosphorylation of this 
complex leads to IκB phosphorylation. This results in IκB ubiquitination and proteasomal 
degradation and NF-κB dimer nuclear translocation where it binds to DNA and causes 




The overall objective of this project was to investigate the potential role of IGPR-
1 in leukemia, in particular the role human-T-cell leukemia virus type 1 (HTLV-1) in the 
regulation of IGPR-1 in leukemia cells. The specific goals of this project were: 
A. Determine the expression and activation of IGPR-1 in leukemic cell lines in cell 
culture.  
B. Determine whether stimulation of IKKβ kinase activity can mediate 
phosphorylation of IGPR-1 at Ser220.  
B. Test the hypothesis that the HTLV-1 gene product oncogene, Tax, via activation 





Cell Lines and Antibodies 
Leukemia cell lines were maintained in Roswell Park Memorial Institute (RPMI) cell 
culture media with 10% fetal bovine serum (FBS). Human embryonic kidney cells (HEK-
293) were grown in Dulbecco’s Modified Eagle’s Media (DMEM) with 10% FBS. Cells 
were stored in a 37oC-humidified incubator and passaged using trypsin/EDTA when cells 
were around 80% confluent.  
Rabbit polyclonal anti-IGPR-1 antibody and anti-phosphoserine220 IGPR-1 
antibody were developed in house (N. Rahimi et al., 2012). Anti-IKK rabbit monoclonal 
antibody was purchased from Invitrogen (Rockford, IL). Anti-pIKK rabbit antibody was 
purchased from Cell Signaling Technology (Danvers, MA). Anti-GAPDH mouse 
antibody was purchased from Santa Cruz Biotechnology (Dallas, TX). Anti-IQGAP1 
rabbit antibody was purchased from Millipore (Temecula, California).  
 
Cell Lysis 
Leukemia cell culture plates were centrifuged for 5 min at 2000 RPM. Media was 
removed and then lysed using lysis (EB) buffer [10mM Tris-HCl (pH 7.5), 1% Triton X-
100, 10mM EDTA, 50 mM NaF, 50mM NaCl], 10µL/ml Na3VO4, and 15µL/ml PIC 
(Protease Inhibitor Cocktail) [500 µM AEBSF, hydrochloride, 150 nM aprotinin, bovine 
lung, crystalline, disodium, 0.5 mM EDTA, 1 µM E-64 protease inhibitor, and 1 µM 
leupeptin, hemisulfate]. Product was again centrifuged for 15 minutes at 12000 RPM. 
The supernatant was collected and 5x sample buffer [5% β-mercaptoethanol, 5% sodium 
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dodecyl sulfate (SDS), 3.8% Tris-base, 50% glycerol, and 0.0025% bromophenol blue] 
was added to solution. Cell lysates were then heated at 95oC for 5 minutes.  
 HEK-293-IGPR1-MYC-PQ cell culture plates were placed ice and washed two 
times with H/S buffer [20mM Hepes (pH 7.4) and 150 mM NaCl] and then lysed using 
lysis (EB) buffer [10mM Tris-HCl (pH 7.5), 10mM EDTA, 50mM NaCl, 1% Triton X-
100, 50 mM NaF], 10µL/ml Na3VO4, and 15µL/ml PIC (Protease Inhibitor Cocktail) [150 
nM aprotinin, hydrochloride, bovine lung, crystalline, 500 µM AEBSF, 1 µM E-64 
protease inhibitor, 0.5 mM EDTA, disodium, and 1 µM leupeptin, hemisulfate]. Product 
was then centrifuged for 15 minutes at 12000 RPM. The supernatant was collected and 
5x sample buffer [5% β-mercaptoethanol, 3.8% Tris-base, 5% sodium dodecyl sulfate 
(SDS), 50% glycerol, and 0.0025% bromophenol blue] was added to solution. Cell 
lysates were then heated at 95oC for 5 minutes. 
 
Western Blot Analysis 
Cell lysates were loaded on a 12% SDS polyacrylamide gel electrophoresis (SDS-
PAGE). Protein was then transferred to polyvinylidene difluoride (PVDF) membranes 
pre-activated with methanol. Membranes were blocked with Blotto (0.05 % Tween-20 in 
Western Rinse and 2% non-fat dry milk) overnight. Primary antibodies were made from 
block (2% bovine serum albumin (BSA) and 0.05% Tween-20 in Western rinse) and anti-
rabbit secondary antibodies were made in blotto. Membranes were immunoblotted with 
primary and secondary antibodies for 1 hour on a shaker. After both primary and 
secondary antibody steps, membranes were washed three times for 10 minutes each with 
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western rinse. Proteins were detected with enhanced chemiluminescence (ECL) and then 
the film developed.  
 
LPS Experiments 
Cells were grown to 80% confluency and then administered with different concentrations 
of LPS overnight and lysed.  
 
Plasmid and Constructs 
Plasmids of pCVMV4-Tax WT, pCMV4-TAX (M20), and IKK2 S177E/S181E pCMV-
FLAG were purchased from Addgene (Watertown, MA) and transformed into and 
purified from bacteria.  
 
Cell Transfection 
HEK-293-IGPR1-MYC-PQ cells were grown to 60% confluency in DMEM 10% FBS 
media. Media was removed from plate and replaced with 2mL of serum free DMEM. 
DNA-PEI (polyethylenimine) mixture was made from 400µL of serum free DMEM, 9ng 
of PEI, and 3µg of DNA (pCMV-4 TAX-WT or pCMV-4 TAX-M20). After 15 minutes, 
the DNA-PEI mixture was added to cells and then reincubated at 37°C. 6 hour later, 2mL 
of DMEM 10% FBS media was added. All media was removed from plates and replaced 






IGPR-1 Expression in Leukemia Cell Lines 
To begin the investigation of IGPR-1 function in leukemia, publically available data from 
The Catalogue of Somatic Mutations In Cancer (COSMIC) was used to analyze 
expression levels of IGPR-1 in different cell lines. The results showed that all the 
leukemia cell lines tested express IGPR-1.  
 
Figure 4. IGPR-1 Expression in Leukemia Samples 
IGPR-1 is found to be overexpressed in leukemia cell lines. 
 
To validate these results, western blot analysis was used to probe different leukemia cell 
lines for IGPR-1. This experiment similarly suggests a high expression of IGPR-1 in 
leukemia cell lines. There exists some variation in the amount of IGPR-1 between 
different cell lines, but overall, IGPR-1 is shown to be upregulated. In addition, these 







































































































Figure 5. IGPR-1 Expression in Leukemia Cell Lines 
Leukemia cell lysates were probed for IGPR-1 antibody and subjected to western 
analysis. IQGAP1 was used as a protein loading control.  
 
IKKβ Regulates Phosphorylation of IGPR-1 
There exists evidence on the role of Akt in both the IGPR-1 and NF-κB pathways (Bai et 
al., 2010) (Woolf et al., 2017). Therefore, an experiment was designed to investigate a 
possible relationship between IKK and IGPR-1 phosphorylation. HEK293-IGPR-1-
MYC-PQ cells were administered with an IKKβ inhibitor to see if by inhibiting IKKβ, 
there would be an effect on IGPR-1 phosphorylation. Western blot analysis showed a 
decrease in the amount of Ser220 phosphorylation in response to an increase in the 




Figure 6. IKKβ Mediates Phosphorylation of IGPR-1 at Ser220 
HEK293-IGPR1-MYC-PQ cells were prepared with different concentrations of an IKK 
inhibitor. (Courtesy of Tooba Alwani) 
 
In order to see the effect of an increase IKK activation on IGPR-1 activation, cells were 
treated with lipopolysaccharide (LPS), a potent activator for IKKβ (Liu et al., 2018). 
Various concentrations of LPS were administered to cells overnight and then lysed. 
Western blot analysis was performed on HEK293-IGPR1-MYC-PQ cells. The 
experiment showed that an increase in the amount of LPS administered to cells led to an 




Figure 7. LPS Stimulates Phosphorylation of IGPR-1 at Ser220  
Cell lysates from HEK293-IGPR1-MYC-PQ cell lines were prepared with different 
concentrations of LPS. GAPDH was used as a loading control. 
 
 
To further establish that IKK may be able to mediate IGPR-1 activation, cells were 
transfected with a constitutively active IKK plasmid. The data revealed that when 
compared to an empty vector state, cells containing a constitutively active IKK plasmid 
displayed an increase in IGPR-1 phosphorylation. This correlates with the previous 
observation that an increase in the activation of IKK led to an increase in the 




Figure 8. IKK Promotes Phosphorylation of IGPR-1 at Ser220 
Cell lysates from HEK293-IGPR1-MYC-PQ cell lines were transfected with IKK2 
S177E/S181E pCMV-FLAG or empty vector PMSCV. GAPDH was used as a loading 
control. 
 
Tax, an oncoprotein encoded by human-T-cell leukemia virus type 1 (HTLV-1), activates 
the IKK complex. To test if IGPR-1 may play a functional role in response to Tax and the 
activation of IKK, HEK293-IGPR1-MYC-PQ cells were transfected with wild type 
pCVMV4-TAX WT and mutant pCMV4-TAX (M20) plasmids. Western blot analysis 
showed that transfection of these cells in both wild type and mutant plasmid conditions 





Figure 9. Tax Promotes the Inhibition of Phosphorylation of IGPR-1 at Ser220 
Cell lysates from HEK293-IGPR1-MYC-PQ cell lines were transfected with pCMV-






IGPR-1 is a novel cell surface receptor that is highly expressed in endothelial cells. 
Current data has demonstrated its involvement in several biological functions such as 
angiogenesis, cell adhesion, and cell morphology (N. Rahimi et al., 2012). Furthermore, 
IGPR-1 expression is found to be upregulated in colorectal cancer cells. IGPR-1 has a 
prosurvival effect on these cells as shown through proliferation assays and mouse tumor 
models (Woolf et al., 2017). In addition, a relationship was found between IGPR-1 and 
chemotherapeutic resistance in response to doxorubicin (Woolf et al., 2017). Lastly, 
IGPR-1 has been identified as a binding partner for HHLA2, which provides a promising 
new approach to cancer therapy (Janakiram et al., 2017).   
This recent study investigates the role of IGPR-1 in leukemia cells. Publically available 
data from The Catalogue of Somatic Mutations In Cancer (COSMIC) showed a high 
expression of IGPR-1 in the leukemia cell lines tested. Similarly, western blot analysis 
confirmed the expression of IGPR-1 in leukemia cells. However, the data showed varying 
levels of IGPR-1 expression between different cell lines and therefore raises the 
possibility of a relationship between different types of cancer and IGPR-1 expression 
level. Data analysis also showed phosphorylation of IGPR-1 at Ser220 for these cell lines 
tested. Taken together, this demonstrates that IGPR-1 is highly expressed and also 
activated in leukemia cell lines. 
Previous data has shown that IGPR-1 is activated through an Akt dependent pathway 
(Woolf et al., 2017). Furthermore, Akt plays an essential role in the phosphorylation and 
activation of the IKK complex in the NF-κB pathway (Bai et al., 2010). Therefore to 
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investigate if IKK can mediate the phosphorylation of IGPR-1, an IKKβ inhibitor was 
administered to HEK293-IGPR1-MYC-PQ cells. These cell lines were created as a model 
system to better see the effect on cells overexpressing IGPR-1. Western blot analysis 
showed that an increase in the amount of IKKβ inhibitor led to a decrease in 
phosphorylated Ser220, suggesting a relationship between IGPR-1 and IKK.  
To further study this relationship between IKK and IGPR-1, lipopolysaccharide (LPS) 
was administered to HEK293-IGPR1-MYC-PQ cells. LPS is a large molecule that plays 
an essential role in the phosphorylation and activation of the IKK complex (Liu et al., 
2018). Analysis showed that an increase in LPS led to an increase in the amount of 
phosphorylated Ser220. These results taken together indicate that IKK activation results 
in the activation of IGPR-1. 
To confirm the hypothesis that IKK activation leads to IGPR-1 activation, HEK293-
IGPR1-MYC-PQ cells were transfected with IKK2 S177E/S181E, a constitutively active 
IKK plasmid. These results revealed that when cells were treated with this plasmid, there 
was an increase in the phosphorylation of Ser220 when compared to an empty vector 
condition. This also closely aligns with the previous data that IGPR-1 gets activated in 
response to IKK activation. Furthermore, this data also confirms the previous observation 
that LPS activates IKK and Ser220. Cells treated with LPS overnight led to an increase in 
Ser220 even in the presence of the IKK2 plasmid. 
The last experiment was designed to test for a functional role of IGPR-1 in leukemia. 
Previous data has indicated that Tax has the ability to activate IKK and the NF-κB 
pathway in the development of adult T-cell leukemia (ATL) (Shibata et al., 2017). 
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However, when HEK293-IGPR1-MYC-PQ cells were transfected with Tax wild type and 
mutant plasmids, a decrease in the phosphorylation of Ser220 was observed. These 
results are in contrast to the previous experimental data where IKK activation showed an 
increase in IGPR-1. Therefore, it is hypothesized that Tax may lead to a 
dephosphorylation of IGPR-1 through the activation of a phosphatase. A possible 
mechanism for this Tax-mediated inhibition of IGPR-1 phosphorylation may be due to 
the effect of protein phosphatase 1D (PPM1D). PPM1D is a Ser/Thr phosphatase that is 
overexpressed in leukemia (Kamada, Kudoh, Yoshimura, Tanino, & Sakaguchi, 2017). It 
functions as a negative regulator of the p53 tumor suppressor and therefore represents a 
promising explanation for the dephosphorylation of IGPR-1. Further studies on this 
relationship between IKK and IGPR-1 may shed new light on the role of IGPR-1 in the 
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